{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:29:45Z","timestamp":1771500585427,"version":"3.50.1"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1582,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1365-2036.2011.04679.x","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T04:07:57Z","timestamp":1304482077000},"page":"1-10","source":"Crossref","is-referenced-by-count":103,"title":["Review article: causative factors and the clinical management of patients with Crohn\u2019s disease who lose response to anti-TNF-\u03b1 therapy"],"prefix":"10.1111","volume":"34","author":[{"given":"S.","family":"Danese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2009.02.001","article-title":"Biological therapies for inflammatory bowel diseases","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2\u2003years of therapy for Crohn\u2019s disease","volume":"31","author":"Colombel","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Pan\u00e9s","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Feagan","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ibd.21259","article-title":"Monitoring functional serum antitumor necrosis factor antibody level in Crohn\u2019s disease patients who maintained and those who lost response to anti-TNF","volume":"16","author":"Sono","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270008316886","article-title":"Population pharmacokinetics of infliximab in patients with ankylosing spondylitis","volume":"48","author":"Xu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.2009.09563.x","article-title":"Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study","volume":"162","author":"Pink","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomised, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2036.2010.04523.x","article-title":"The efficacy of shortening the dosing interval to once every six weeks in Crohn\u2019s patients losing response to maintenance dose of infliximab","volume":"33","author":"Kopylov","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapy efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2005.02424.x","article-title":"Review article: smoking cessation as primary therapy to modify the course of Crohn\u2019s disease","volume":"21","author":"Johnson","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB27|cit27","first-page":"85","article-title":"Similar response to adalimumab in patients with active Crohn\u2019s disease either naive to biologic agents or with prior loss of response or intolerance to infliximab","volume":"114","author":"Triantafillidis","year":"2010","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB28|cit28","doi-asserted-by":"crossref","DOI":"10.1016\/S1873-9946(09)60022-2","article-title":"Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn\u2019s disease in the United States","volume":"3","author":"Loftus","year":"2009","journal-title":"J Crohns Colitis"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/gene.2010.34","article-title":"Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis","volume":"11","author":"van Baarsen","year":"2010","journal-title":"Genes Immun"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB31|cit31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011310","article-title":"The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis","volume":"5","author":"Lindberg","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/ibd.21301","article-title":"Predictive value of epithelial gene expression profiles for response to infliximab in Crohn\u2019s disease","volume":"16","author":"Arijs","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB34|cit34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MEG.0b013e32832937e3","article-title":"A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab","volume":"21","author":"Mantzaris","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ajg.2010.158","article-title":"Predictors of infliximab failure after azathioprine withdrawal in Crohn\u2019s disease treated with combination therapy","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ibd.21328","article-title":"Dosage adjustment during long-term adalimumab treatment for Crohn\u2019s disease: clinical efficacy and pharmacoeconomics","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2010.03.024","article-title":"Reinduction with certolizumab pegol in patients with relapsed Crohn\u2019s disease: results from the PRECiSE 4 Study","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","article-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohn\u2019s disease for up to 18\u2003months","volume":"8","author":"Lichtenstein","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1365-2036.2007.03548.x","article-title":"Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn\u2019s disease: a cost-effectiveness analysis","volume":"26","author":"Kaplan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2036.2009.04101.x","article-title":"Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"30","author":"Ma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn\u2019s disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn\u2019s disease after failure of two other anti-TNF antibodies","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB53|cit53","unstructured":"http:\/\/www.clinicaltrial.gov\/ct2\/show\/NCT00771667?term=ustekinumab+AND+Crohn&rank=1"},{"key":"10.1111\/j.1365-2036.2011.04679.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ibd.20833","article-title":"Extracorporeal photopheresis for the treatment of refractory Crohn\u2019s disease: results of an open-label pilot study","volume":"15","author":"Abreu","year":"2009","journal-title":"Inflamm Bowel Dis"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04679.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04679.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T21:15:13Z","timestamp":1625433313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04679.x"}},"subtitle":["Review: loss of response to anti-TNFs in Crohn\u2019s disease"],"short-title":[],"issued":{"date-parts":[[2011,5,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04679.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,3]]}}}